NASDAQ:OTIC - Otonomy Stock Price, News, & Analysis

$2.52
-0.01 (-0.40 %)
(As of 07/17/2019 04:00 PM ET)
Today's Range
$2.49
Now: $2.52
$2.52
50-Day Range
$2.31
MA: $2.54
$2.75
52-Week Range
$1.50
Now: $2.52
$3.95
Volume2,738 shs
Average Volume29,569 shs
Market Capitalization$77.31 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OTIC
CUSIPN/A
Phone619-323-2200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$750,000.00
Book Value$2.60 per share

Profitability

Net Income$-50,370,000.00
Net Margins-8,007.55%

Miscellaneous

Employees49
Market Cap$77.31 million
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable

Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter.

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How were Otonomy's earnings last quarter?

Otonomy Inc (NASDAQ:OTIC) announced its quarterly earnings data on Monday, May, 6th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.07. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.33 million. Otonomy had a negative net margin of 8,007.55% and a negative return on equity of 60.14%. View Otonomy's Earnings History.

When is Otonomy's next earnings date?

Otonomy is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Otonomy.

What price target have analysts set for OTIC?

3 analysts have issued 12 month price objectives for Otonomy's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Otonomy's share price to reach $7.50 in the next year. This suggests a possible upside of 197.6% from the stock's current price. View Analyst Price Targets for Otonomy.

What is the consensus analysts' recommendation for Otonomy?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.

What are Wall Street analysts saying about Otonomy stock?

Here are some recent quotes from research analysts about Otonomy stock:
  • 1. According to Zacks Investment Research, "Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle ear effusion; and OTO-104 for the treatment of patients with Ménière's disease. Otonomy, Inc. is headquartered in San Diego, California. " (7/17/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month price target of $5 per share on OTIC. On Monday, after market close, Otonomy reported 4Q18 revenues of $0.208M and cash of $97.3M. Our model projects current cash will provide two years of runaway (into 2021), which should include readout of the P3 study of OTIVIDEX for Ménière’s disease in 2020. We also expect to hear about" the initiation of a P1/2 study of OTO-313 for tinnitus in 2Q19 and a in hearing loss in 3Q19, with data from these two studies also expected in 2020. Questions on the call centered around the P3 OTIVIDEX study in which enrollment appears on track for study completion in 1H20." (3/4/2019)

Has Otonomy been receiving favorable news coverage?

News articles about OTIC stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Otonomy earned a news impact score of -1.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Otonomy.

Are investors shorting Otonomy?

Otonomy saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 122,300 shares, a decrease of 13.4% from the April 15th total of 141,200 shares. Based on an average daily volume of 126,600 shares, the short-interest ratio is presently 1.0 days. Currently, 0.4% of the company's stock are sold short. View Otonomy's Current Options Chain.

Who are some of Otonomy's key competitors?

What other stocks do shareholders of Otonomy own?

Who are Otonomy's key executives?

Otonomy's management team includes the folowing people:
  • Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)
  • Dr. David Allen Weber, Pres, CEO & Director (Age 59)
  • Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)
  • Mr. Robert Michael Savel II, Chief Technical Officer (Age 51)
  • Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $2.52.

How big of a company is Otonomy?

Otonomy has a market capitalization of $77.31 million and generates $750,000.00 in revenue each year. The biopharmaceutical company earns $-50,370,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Otonomy employs 49 workers across the globe.View Additional Information About Otonomy.

What is Otonomy's official website?

The official website for Otonomy is http://www.otonomy.com/.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]


MarketBeat Community Rating for Otonomy (NASDAQ OTIC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel